HemaCare Corp. and Charles River Labs have formed a strategic partnership to advance human immune system research by developing a more efficient and reliable method of working with humanized mice.
 
HemaCare’s peripheral blood mononuclear cells (PBMCs) will be integrated into Charles River’s NCG/PBMC Select Humanization Kit. This kit is the first of its kind and aims to provide both the NCG mouse and vials of pre-selected human PBMCs, allowing researchers to efficiently develop the humanized mouse model.
 
The key to the creation of humanized mice is the engraftment of human PBMCs, which allows for development of human immune systems. The challenges that researchers often face is that engraftment varies with each PBMC donor. By evaluating human PBMCs from donors in advance, optimal donors can be identified, pre-qualified, and their cells included in the humanized mouse model kit.
 
“In drug discovery and development, humanized mouse models have emerged as an essential tool in researching novel therapies for patients,” said Iva Morse, corporate vice president, chief scientific officer, Global RMS at Charles River. “We’ve formed a strategic alliance with HemaCare because they have one of the largest donor databases in the world, an FDA-approved collection center, and the ability to pre-screen and qualify the donors.”
 
“HemaCare continues to develop strategic partnerships to expand the breadth and depth of our product portfolio,” said Lou Juliano, HemaCare’s senior vice president of Global Sales and Business Development. “Charles River and HemaCare are both deeply committed and laser-focused on helping researchers with their mouse humanization needs. Optimized human mouse models can accelerate drug discovery and ultimately improve patient outcomes.”